Deep Vein Thrombosis Management

Immediate Anticoagulation

The American College of Cardiology recommends initiating treatment immediately with a direct oral anticoagulant (DOAC) such as rivaroxaban or apixaban for most patients with acute DVT, due to superior safety profiles and comparable efficacy 1
Anticoagulation should be started immediately upon diagnosis, even while awaiting confirmatory testing if clinical suspicion is high, with DOACs being the first-line agents for most patients with DVT 1, 2
When selecting a DOAC, consider renal function, with apixaban having only 25% renal clearance versus dabigatran with ~80% renal clearance, and once-daily versus twice-daily dosing preferences 2

Home treatment is preferred over hospitalization for uncomplicated DVT when appropriate home circumstances exist, according to the American College of Physicians 1
Hospital admission is required for massive DVT with severe pain, swelling of entire limb, phlegmasia cerulea dolens, or limb ischemia, as well as high bleeding risk, hemodynamic instability, or severe cardiac/respiratory disease 2

For extensive iliofemoral DVT in younger patients at low bleeding risk, catheter-directed thrombolysis (CDT) or pharmacomechanical catheter-directed thrombolysis (PCDT) should be considered to prevent post-thrombotic syndrome, with a strength of evidence of moderate to high 3, 2
CDT plus anticoagulation results in better 6-month venous patency and less functional venous obstruction compared with anticoagulation alone, with a relative risk reduction of 40-50% 2

For cancer patients with DVT, the National Comprehensive Cancer Network recommends LMWH monotherapy over DOACs or warfarin, due to higher VTE recurrence rates and bleeding risk 4, 1, 2
LMWH should be used at 75-80% of the initial dose for long-term treatment, and continued as long as there is clinical evidence of active malignant disease 4

The American College of Phlebology recommends starting 30-40 mm Hg knee-high graduated elastic compression stockings within one month of diagnosis, and continuing for at least 1-2 years after diagnosis of iliofemoral DVT, to reduce post-thrombotic syndrome incidence from 47% to 20% 2

IVC filters are not routinely recommended in addition to anticoagulant therapy for DVT, according to the Society of Interventional Radiology, but may be considered for recurrent PE despite adequate anticoagulation or absolute contraindications to anticoagulation 1, 2, 4, 3

Regular assessment of renal function is necessary when using DOACs, as dosing may require adjustment, with a frequency of at least every 6-12 months 1
Patients on extended anticoagulation therapy should be reassessed periodically, ideally every 6-12 months, to evaluate the risk-benefit ratio of continued anticoagulation 1

The American College of Obstetricians and Gynecologists recommends using LMWH instead of warfarin due to teratogenicity risk, and DOACs are also contraindicated in pregnancy 2

For VTE recurrence on warfarin with subtherapeutic INR, retreat with UFH or LMWH until therapeutic anticoagulation is achieved, according to the International Society on Thrombosis and Haemostasis 4
For recurrence on therapeutic warfarin, switch to LMWH or increase INR target to 3.5, with a strength of evidence of moderate to high 4